ES2599635T3 - Inmunoanálisis para la cuantificación de un antígeno inestable seleccionado de BNP y proBNP - Google Patents
Inmunoanálisis para la cuantificación de un antígeno inestable seleccionado de BNP y proBNP Download PDFInfo
- Publication number
- ES2599635T3 ES2599635T3 ES08736833.8T ES08736833T ES2599635T3 ES 2599635 T3 ES2599635 T3 ES 2599635T3 ES 08736833 T ES08736833 T ES 08736833T ES 2599635 T3 ES2599635 T3 ES 2599635T3
- Authority
- ES
- Spain
- Prior art keywords
- bnp
- probnp
- order
- antibody
- immunocomplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100036836 Natriuretic peptides B Human genes 0.000 title claims abstract description 47
- 101710187802 Natriuretic peptides B Proteins 0.000 title claims abstract description 47
- 238000003018 immunoassay Methods 0.000 title claims abstract description 21
- 239000000427 antigen Substances 0.000 title description 35
- 102000036639 antigens Human genes 0.000 title description 35
- 108091007433 antigens Proteins 0.000 title description 35
- 238000011002 quantification Methods 0.000 title description 3
- 239000012634 fragment Substances 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 68
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 68
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 206010019280 Heart failures Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102400001263 NT-proBNP Human genes 0.000 description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2470/00—Immunochemical assays or immunoassays characterised by the reaction format or reaction type
- G01N2470/04—Sandwich assay format
- G01N2470/06—Second binding partner specifically binding complex of analyte with first binding partner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91160307P | 2007-04-13 | 2007-04-13 | |
| FI20075251A FI20075251A0 (fi) | 2007-04-13 | 2007-04-13 | Immunomääritys epästabiilien antigeenien määrittämiseksi |
| US911603P | 2007-04-13 | ||
| FI20075251 | 2007-04-13 | ||
| PCT/FI2008/050184 WO2008125733A1 (en) | 2007-04-13 | 2008-04-14 | Immunoassay for quantification of an unstable antigen selected from bnp and probnp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2599635T3 true ES2599635T3 (es) | 2017-02-02 |
Family
ID=38009904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08736833.8T Active ES2599635T3 (es) | 2007-04-13 | 2008-04-14 | Inmunoanálisis para la cuantificación de un antígeno inestable seleccionado de BNP y proBNP |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9034591B2 (enExample) |
| EP (1) | EP2135087B1 (enExample) |
| JP (1) | JP5686593B2 (enExample) |
| CN (1) | CN101842707B (enExample) |
| CA (1) | CA2683911C (enExample) |
| DK (1) | DK2135087T3 (enExample) |
| ES (1) | ES2599635T3 (enExample) |
| FI (1) | FI20075251A0 (enExample) |
| WO (1) | WO2008125733A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2919611B1 (fr) | 2007-08-03 | 2009-10-23 | Bio Rad Pasteur Sa | Nouvel epitope du bnp (1-32) et anticorps diriges contre cet epitope |
| EP2601531A1 (en) | 2010-08-04 | 2013-06-12 | IDEXX Laboratories, Inc. | Detection of degradation products of canine nt-probnp |
| JP2012140331A (ja) * | 2010-12-28 | 2012-07-26 | Tosoh Corp | タグペプチド |
| CA2864868A1 (en) | 2011-02-25 | 2012-11-15 | Wellstat Diagnostics, Llc | Assays for detecting enzymatic activity |
| AU2012262154B2 (en) | 2011-05-31 | 2016-08-04 | Idexx Laboratories, Inc. | Detection of degradation products of feline NT-proBNP |
| IN2014CN02113A (enExample) * | 2011-09-21 | 2015-05-29 | Fujirebio Kk | |
| CN102608335A (zh) * | 2012-04-19 | 2012-07-25 | 协和生物制药（天津）有限公司 | NT-proBNP时间分辨荧光免疫分析试剂盒的制备方法 |
| EP4014041A1 (en) | 2019-08-13 | 2022-06-22 | Gentian AS | Highly sensitive particle enhanced assay for the quantification of nt-probnp |
| CN113956355B (zh) * | 2021-07-26 | 2023-06-23 | 无锡傲锐东源生物科技有限公司 | 抗人脑利钠肽(bnp)兔单克隆抗体及其应用 |
| CN118119849A (zh) | 2021-10-01 | 2024-05-31 | 挪威金田有限公司 | 测定样品中N末端激素原BNP(NT-proBNP)浓度的新方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583003A (en) * | 1989-09-25 | 1996-12-10 | Agen Limited | Agglutination assay |
| WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| DE69833118T2 (de) | 1997-09-11 | 2006-08-31 | Shionogi & Co., Ltd. | Immunoassay zum bestimmen von bnp |
| US20030219734A1 (en) | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
| CA2430889A1 (en) | 2002-06-19 | 2003-12-19 | Bayer Corporation | Stabilization of brain natriuretic peptide (bnp) in blood samples, methods and compositions related thereto |
| FI20022048A0 (fi) * | 2002-11-18 | 2002-11-18 | Valtion Teknillinen | Ei-kompetetiivinen immunomääritys pienille analyyteille |
| KR100771999B1 (ko) * | 2004-05-20 | 2007-10-31 | 김상돈 | 그레이팅 |
| US7731965B2 (en) | 2005-02-17 | 2010-06-08 | Abbott Lab | Human ring specific BNP antibodies |
| JP5364378B2 (ja) | 2005-11-09 | 2013-12-11 | アボット・ラボラトリーズ | ヒトｂｎｐ免疫特異的抗体 |
| EP2021369A2 (en) | 2006-05-26 | 2009-02-11 | Hytest Ltd. | Antibodies and standard for nt-probnp and probnp immunoassays |
| US20080064045A1 (en) | 2006-09-07 | 2008-03-13 | Huaiqin Wu | Biomarker fragments for the detection of human BNP |
-
2007
- 2007-04-13 FI FI20075251A patent/FI20075251A0/fi unknown
-
2008
- 2008-04-14 WO PCT/FI2008/050184 patent/WO2008125733A1/en not_active Ceased
- 2008-04-14 DK DK08736833.8T patent/DK2135087T3/en active
- 2008-04-14 CA CA2683911A patent/CA2683911C/en active Active
- 2008-04-14 EP EP08736833.8A patent/EP2135087B1/en active Active
- 2008-04-14 JP JP2010502538A patent/JP5686593B2/ja active Active
- 2008-04-14 US US12/595,463 patent/US9034591B2/en active Active
- 2008-04-14 ES ES08736833.8T patent/ES2599635T3/es active Active
- 2008-04-14 CN CN200880011741.2A patent/CN101842707B/zh active Active
-
2012
- 2012-08-31 US US13/600,873 patent/US9034592B2/en active Active
-
2015
- 2015-04-17 US US14/689,486 patent/US9145459B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5686593B2 (ja) | 2015-03-18 |
| EP2135087B1 (en) | 2016-09-14 |
| FI20075251A0 (fi) | 2007-04-13 |
| US20150219675A1 (en) | 2015-08-06 |
| EP2135087A4 (en) | 2011-06-22 |
| US20130071949A1 (en) | 2013-03-21 |
| CN101842707B (zh) | 2016-11-09 |
| CA2683911C (en) | 2017-01-10 |
| DK2135087T3 (en) | 2016-11-14 |
| US9034592B2 (en) | 2015-05-19 |
| JP2010523994A (ja) | 2010-07-15 |
| US9145459B2 (en) | 2015-09-29 |
| US20100203560A1 (en) | 2010-08-12 |
| EP2135087A1 (en) | 2009-12-23 |
| WO2008125733A1 (en) | 2008-10-23 |
| CA2683911A1 (en) | 2008-10-23 |
| US9034591B2 (en) | 2015-05-19 |
| CN101842707A (zh) | 2010-09-22 |
| WO2008125733A8 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2599635T3 (es) | Inmunoanálisis para la cuantificación de un antígeno inestable seleccionado de BNP y proBNP | |
| WO2005052593A1 (en) | Detection | |
| US20070249005A1 (en) | Gastrin hormone immunoassays | |
| ES2346550T3 (es) | Determinacion de probnp felino o canino. | |
| US20230032690A1 (en) | New tau species | |
| US11719697B2 (en) | Immunoassay and antibodies for the detection of chromogranin A | |
| JPWO2016140063A1 (ja) | オキシトシンの高感度測定法 | |
| JP2024056971A (ja) | ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法 | |
| KR20220063139A (ko) | 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법 | |
| HK1147801B (en) | Immunoassay for quantification of an unstable antigen selected from bnp and probnp | |
| HK1147801A (en) | Immunoassay for quantification of an unstable antigen selected from bnp and probnp | |
| WO2018220108A1 (en) | Biomarker molecules for sarcopenia and uses thereof |